LOS ALTOS, CA, USA I April 25, 2016 I Today, AbGenomics International Inc., a privately-held clinical-stage biopharmaceutical company developing targeted antibody therapeutics for the treatment of immune-mediated inflammatory diseases and cancers, announced promising results from the company’s open-label Phase II study (ClinicalTrials.gov Identifier: NCT02267642). This study, which was conducted by seven clinical experts in immunology and rheumatology, investigated AbGenomics’ lead compound AbGn168H/Neihulizumab in Psoriatic Arthritis (PsA), a T-cell mediated disease. The company also intends to advance this candidate into treatment of other T-cell mediated inflammatory diseases with strong unmet medical needs, such as acute GvHD and new onset of type-I diabetes.
The results of this 20-patient open-label Phase II study showed improvement in each of the evaluated efficacy parameters. The overall efficacy analysis indicated that 40% of all enrolled patients treated with AbGn-168H demonstrated meaningful responses by Week 12. Importantly, the results of an ad hoc analysis of 15 patients who received all 7 doses of AbGn-168H and completed the study (Completed Set) identified 8 responders who achieved a 20% reduction in PsA symptoms according to the American College of Rheumatology, or ACR20 (53.3%), 6 ACR50 responders (40%) and 2 ACR70 responders (13.3%) at Week 12, suggesting there is clinical utility with this agent for the treatment of psoriatic arthritis. The treatment was well-tolerated in this population, and no evidence of increased incidence of infection was observed.
“We are very pleased with the results of this proof of concept study of our lead compound in psoriatic arthritis, a progressively painful and debilitating inflammatory disease. With a unique mechanism of action that induces cell apoptotic death only in over-proliferating T-cells, AbGn-168H has great potential to safely and effectively treat a variety of inflammatory diseases, including acute GvHD, transplant rejections, new onset of type-I diabetes, IBD/Crohn’s, multiple sclerosis, rheumatoid arthritis, and allergic diseases.” said Ron Lin, Ph.D., CEO of AbGenomics.
About AbGenomics (www.abgenomics.com)
AbGenomics International Inc. (AbG), incorporated in Delaware in 2006 with its principal office in San Francisco Bay Area, California, is a clinical stage biopharmaceutical company to develop targeted antibody therapeutics for the treatment of cancers and immune mediated inflammatory diseases with significant unmet medical needs. AbGenomics has built a strong patent portfolio to protect our best-in-class therapeutic product candidates. Our lead candidate AbGn-168H/Neihulizumab has demonstrated the proof of clinical efficacy in phase-II clinical trials for T-cell mediated diseases such as psoriasis and psoriatic arthritis patients. This innovative drug candidate has the potential to bring game-changing benefit for the patients with several other T-cell mediated diseases. Another important asset of the company is our proprietary ADC technology and products. We are able to demonstrate the superior benefits and competitive strength of our biosuperior ADCs over existing ADCs in the market or those under development.
Note on Forward-Looking Statements
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as expects, believes, intends, and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, and risks related to the Company’s ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.
SOURCE: AbGenomics
Post Views: 72
LOS ALTOS, CA, USA I April 25, 2016 I Today, AbGenomics International Inc., a privately-held clinical-stage biopharmaceutical company developing targeted antibody therapeutics for the treatment of immune-mediated inflammatory diseases and cancers, announced promising results from the company’s open-label Phase II study (ClinicalTrials.gov Identifier: NCT02267642). This study, which was conducted by seven clinical experts in immunology and rheumatology, investigated AbGenomics’ lead compound AbGn168H/Neihulizumab in Psoriatic Arthritis (PsA), a T-cell mediated disease. The company also intends to advance this candidate into treatment of other T-cell mediated inflammatory diseases with strong unmet medical needs, such as acute GvHD and new onset of type-I diabetes.
The results of this 20-patient open-label Phase II study showed improvement in each of the evaluated efficacy parameters. The overall efficacy analysis indicated that 40% of all enrolled patients treated with AbGn-168H demonstrated meaningful responses by Week 12. Importantly, the results of an ad hoc analysis of 15 patients who received all 7 doses of AbGn-168H and completed the study (Completed Set) identified 8 responders who achieved a 20% reduction in PsA symptoms according to the American College of Rheumatology, or ACR20 (53.3%), 6 ACR50 responders (40%) and 2 ACR70 responders (13.3%) at Week 12, suggesting there is clinical utility with this agent for the treatment of psoriatic arthritis. The treatment was well-tolerated in this population, and no evidence of increased incidence of infection was observed.
“We are very pleased with the results of this proof of concept study of our lead compound in psoriatic arthritis, a progressively painful and debilitating inflammatory disease. With a unique mechanism of action that induces cell apoptotic death only in over-proliferating T-cells, AbGn-168H has great potential to safely and effectively treat a variety of inflammatory diseases, including acute GvHD, transplant rejections, new onset of type-I diabetes, IBD/Crohn’s, multiple sclerosis, rheumatoid arthritis, and allergic diseases.” said Ron Lin, Ph.D., CEO of AbGenomics.
About AbGenomics (www.abgenomics.com)
AbGenomics International Inc. (AbG), incorporated in Delaware in 2006 with its principal office in San Francisco Bay Area, California, is a clinical stage biopharmaceutical company to develop targeted antibody therapeutics for the treatment of cancers and immune mediated inflammatory diseases with significant unmet medical needs. AbGenomics has built a strong patent portfolio to protect our best-in-class therapeutic product candidates. Our lead candidate AbGn-168H/Neihulizumab has demonstrated the proof of clinical efficacy in phase-II clinical trials for T-cell mediated diseases such as psoriasis and psoriatic arthritis patients. This innovative drug candidate has the potential to bring game-changing benefit for the patients with several other T-cell mediated diseases. Another important asset of the company is our proprietary ADC technology and products. We are able to demonstrate the superior benefits and competitive strength of our biosuperior ADCs over existing ADCs in the market or those under development.
Note on Forward-Looking Statements
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as expects, believes, intends, and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, and risks related to the Company’s ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.
SOURCE: AbGenomics
Post Views: 72
